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Closing in on the MEN2A Locus
Nancy E. Simpson,* and Kenneth K. Kidd'

The mapping ofthe locusfor multiple endocrine neoplasia type 2A (MEN 2A) to chromosome 10 using
linkage is briefly reviewed including a discussion of linkage strategy and reference to some ofthe
exclusions before the assignment. The subsequent development ofthe map ofthe centromeric region of
the chromosome and the linking of what appear to be the four closest flanking markers and the
centromeric alphoid sequence to the disease locus are reviewed. To date no recombination has been
observed between the centromeric marker and the MEN2A locus among, at leasl, 26 informative
meioses, 11 ofwhich are phase known. While no obligate recombination has been observed between
the markers FNRB, D10S34, and RBP3 and the MEN2A locus in males, d has been observed in
females and is as much as 10% for the marker RBP3. The sex difference in recombination frequency is
significant. The four polymorphic flanking markers, FNRB, DI0S34, RBP3, and D10S5, along with
the centromeric marker DlOZl wiU prove to be usefulfor management of the families with the disease.
It wiU be possible in mostfamilies to give a very high (or low) probability for ' 'at risk" members ofthe
families and in some cases the DNA results will be virtually diagnostic. (Henry Ford Hosp Med J
1989:37:100-5)

T

he relation between the apparent allele for multiple endocrine neoplasia type 2A (MEN 2A) and the development of
the three characteristic tumors, medullary thyroid carcinoma
(MTC), pheochromocytoma, and parathyroid adenomas, is
completely unknown. The understanding of diseases that have a
clear mendelian inheritance suggesting that a single allele is responsible for the disease, at least in a given family, has been the
focus of human genetic research since Mendel's theory was rediscovered at the tum of the century. Many diseases usually inherited in a recessive fashion are the resutt of the tack of or an
inactive enzyme coded for by the mutation of a normal allele and
often are recognized by the excess of enzyme substrate. The diseases are refened to as inbom enors of metabolism (1). The understanding of the biochemistry of these diseases has ted to
cures or prevenfion of their clinical manifestations. The etiology
of some, but not all, of the known recessive diseases has been
solved in this mannen The identification of the protein product
of dominant autosomal alleles responsible for human diseases,
however, has not been as successful. Because the individuat diseases are relatively rare, it can be assumed that those individuals
with the disease are heterozygous, ie, they have one allele for
the disease and one for the normal protein product, and although
a reducfion in an enzyme or protein might be recognized, it is
usually more difficult than discovering an absolute lack of an enzyme when no normal allele is present as in the case of the recessive diseases. One strategy for dealing with this problem,
possible now that the DNA code is understood and molecular
techniques have been developed, is first to find the gene by linkage and then use reverse genetics to isolate the gene and thereby
clone it and find the protein product. As MEN 2A is apparentiy
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dominantly inherited, the linkage approach seemed a suitable
method toward understanding how a mutation could determine
this particular cancer syndrome.

Prevalence
Although MEN 2A is considered rare among all cancers, it is
probably not as rare as was thought in the 1960s and 1970s after
it was first described by Sippte (2). When we became interested
in the disease in the mid 1970s, we knew of only two families
with MEN 2A in Canada. Since the disease locus has been assigned to a chromosome and thereby received considerable publicity, we have become aware of at least 16 families in Canada, tn
countries in which active case finding has occurred (Great
Britain, France, and Holland), an even greater increase in the
numberof families has been noted. Dn W. J. Simpson (personal
communication, 1989) at the Princess Margaret Hospital in
Toronto estimates that 25% of patients with MTC have the MEN
2A syndrome and thus a family history of this disease.

Linkage Strategy
There are two important prerequisites for linkage studies of
seases. The first is the availability of several large families in
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which the disease occurs. Our studies began with two Canadian
families in which MEN 2A was segregating (3-5) and soon included an additional Canadian (6,7) and three large American
families (8-10). A second prerequisite is variant forms ofthe
protein coded by a gene or of a DNA sequence even when its
protein product is unknown; the latter are known as anonymous
sequences and both are known as "markers." The markers are
usually not associated with disease, and the variants need to be
common to be useful for linkage studies. They are more useful if
their location on the chromosome is known. Some clue is desirabte but not always available.
In the last decade, particularly in the past five years, the
numberof useful markers has increased exponentially (11). The
use of recombinant DNA techniques and the Southern blot (12)
for the detection of common DNA variafion or restriction fragment length polymorphisms (RFLPs) and the recognition that
RFLPs could be treated as alleles and used as landmarks on the
map by Botstein et al (13) are responsible for this increase.
RFLPs have become a powerful tool for the detection of linkages
between each other and between their loci and those of disease
alleles that code for unknown protein products. Technology has
now made it possible for the generation of a large data base of
markers, ie, landmarks on the genetic map (II). The linkages, if
close, can provide a starting point for reverse genetics which begins with the mapping ofthe disease allele to a small region of a
chromosome through linkage to loci that can be physically
mapped. At this stage much more satisfactory risks compared to
mendelian risks can be given to members of families with genetic diseases. The precise location of the disease allele follows
from short walks and the use of denaturing gradient gel electrophoresis. Once the gene is found it can be isolated, cloned,
and sequenced, tdentification of the disease mutation(s) and the
development of allele specific oligonucleotide probes for direct
diagnosis from DNA derived from a small blood sample will
often be possible. For example, direct diagnosis is now possible
for the Duchenne and Becker muscular dystrophies. The gene
has been isolated and the mutations studied (14-16) which has
led to the identification of the product dystrophin (17) that can
now be studied for the ultimate understanding of the disease
pathology.
Linkages are detected by studies ofthe transmission of the
variants of the markers from parents to their children. To recognize a linkage it must be possible to identify at least two forms or
variants at each locus. As an exampte, we shall designate as alleles AI,A2 at the first and B1,B2 at the second marker locus.
The variation may just as well be at a locus that codes for disease
or normal. In the first example, ifthe loci A and B are linked and
AIBI are together on one and A2B2 are on the other parental
chromosome, they will occur together in their offspring more
often than 50% as expected by Mendel's second law of independent assortment. If the loci are not close (not linked) on the same
chromosome or are on different chromosomes, then Al and Bl
will occur together in the offspring 50% of the time. The frequency of reassortment of two variants when the loci are on the
same chromosome is dependent on the frequency of crossing
over between the two loci in the gametes resulting in the exchange of bits of the chromosome; in our example, crossover
would result in AIB2 or A2BI being on the same chromosome.

Henry Ford Hosp Med J—Vol 37. Nos 3 & 4. 1989

This phenomenon is known as recombination, and its frequency
is a function of the distance between the loci and often is referred
to as theta. The best estimate of theta is measured by the maximum log of the probability (lod score or Z) of linkage versus no
linkage, and when Z 3= 3 the odds for linkage are 1000:1 and
considered significant. A score of Z =s — 2 is considered
grounds for exclusion of linkage.

History of the Search for the MEN2A Locus
Attempts to find a linkage between the locus for MEN 2A and
a marker gene predated the RFLP marker innovation, but a successful linkage of the MEN2A locus to two DNA markers that
had been mapped to chromosome 10 awaited the use of the new
technology (18,19). Searching for a linkage without a clue is like
looking for a needle in a haystack. The search for a MEN2A
linkage began by looking for the needle. First, linkage with the
histocompatibility locus antigen complex was excluded (20,21)
which was followed by the exclusion of a number of loci for protein markers that were already mapped and have been previously
reviewed (22). We then continued the linkage search by pursuing the clue of a putative deletion on chromosome 20 in patients
with MEN 2A reported by Babu et al (23,24). A deletion was not
unexpected as the familial cancer with specific organ sites was
analogous to that of retinoblastoma and Wilms tumor in which
constitutive chromosomal deletions and chromosomal deletions
or rearrangements in the primary tumors had been reported in
some patients (25-31). Our studies led to exclusion of linkage in
the MEN 2A families using two anonymous sequences D20S5
and D20S6 that mapped to the site of the putative deletion,
thereby excluding the deletion site as a possible map position for
the MEN2A locus and the eventual exclusion of most of chromosome 20 (32,33). Other exclusions were reviewed by us (34)
by which time 32% of the genome was excluded.

Finding a Linkage and Chromosomal Assignment
The first hint of a positive linkage came from the thesis of
Goodfellow (35) in which a lod of 1.5 at theta = 0 was reported
for linkage between the disease locus and an anonymous sequence at DI0S5 in one family but not in two other families.
When the data were expanded to include those from five large
families, the significant Iod score of 3.6 was reached at theta =
0.19. By this time the DNA sequence had been mapped to chromosome 10 by in situ hybridization (36), and studies with the
cDNA probe for interstitial retinol binding protein (RBP3),
which had been mapped to chromosome 10 (37) in a region similar to that forthe DI OS 5 locus, indicated thatthe locus for MEN
2A was clearly linked to both chromosome 10 sequences, nearer
to the RBP3 locus than to the DI0S5 locus (18,19). Since RBP3
had been mapped to a fairly broad pericentric area and DI0S5 to
a single q band, it could be inferred that the MEN2A locus was
also in the pericentric region of the chromosome. At this stage it
was atso clear that both of the marker loci were on one side ofthe
disease locus.

The Map of Chromosome 10
The chromosome assignment and linkages of MEN2A stimulated interest in chromosome 10, and 55 and 73 polymorphic
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Table 1
Chromosome 10 Pericentric DNA Markers and their
Polymorphisms*
Locus

Probe

Restriction
Enzymes

Location

D10S24

p7A9

10pl2.2-pl3

FNRB

pGEM-32

IOplI.2

DIOZl

pB/R2
plORPS

10 cen

RBP3

H.4IRBP

lOqll.2

D10S15

TBIRBP9
pMCK2

lOqll.2
IOqll.2

D10S5

p9-12A

I0q21.I

MSPI
Taql
Banli
Kpnl
Htnfl
BGllI
Sad
Mspl
PstI
EcoRV
Hindi
Bglll
Mspl
Taql
PvuII
Rsal
Taql
Hindi
Dral

e
PIC

Locus Pair

Male

0.55

DI0S24-FNRBi:
D10S24-RBP3t
FNRB-DIOZI*
FNRB-RBP3t
DI0Zl-RBP3t
DI0Z1-DI0S15
RBP3-D10SI5
RBP3-D10S5

0,06
0.04
0.00
0.00
0.00

0.71

0.50

0.67

0.49

Table 2
Recombination Frequencies (9) Between the Loci for
MEN2A and Six Pericentric DNA Markers*

e

0
Male

Female

Znia\t

D10S24
FNRB
DIOZl
RBP3!?
D10S15
DIOSS

0.14
0.06i
0.00
0.00
0.05
0.05

0.18
0.09
0.00
O.IO
0.05
0.15

5.98
13.21
12.02
14.05
17.29
7..^4

Male = Female Zmax
5.92
0.15
0.06
13.16
0.00
12.02
0.05
13.05
0.05
17.29
O.II
7.05

*From Wu J. Carson NL. Myers S. et al. The genetic defect in multiple endocrine neoplasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet (in press)
(44).
tMaximum lod .score.
iNo obligate recombinants were observed.
?iSex difference signilicant at P < 0.05.

markers have been isolated and mapped, respectively, to chromosome 10 (38). Some have reasonably refined positions on the
map (38). Furthermore, the Centre d'Etude du Polymorphisme
Humain (CEPH) consortium chose chromosome 10 for their
first consensus map (39). The general interest in the chromosome has made it easier to close in on the MEN2A locus. In
addifion, the original local ization of I Op 11.2-q 11.2 for the RB P3
locus was reduced to q I I . 2 from studies ofa somatic cell hybrid
line in which the only human chromosome was lOq (40), from in
situ data localizing it to I0cen-q24 (41) and from dosage studies
of several human cell lines (42). The reduced localization of
RBP3 suggested that we took for flanking markers on the p arm
near the centromere.
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—
0.03
0.07

Female
0.22
0.35
0.07
0.18
0.07

—
<0.01
0 07

Zmaxt
19.5
25.5
30.3
36.3
31.1

—
46.6
19.0

0
Male = Female Zmax
0.14
0.16
0.04
O.IO
0.04
0.05
0.02
0.07

17.7
18.2
28.2
30.3
29.3
11.93
45.9
19.0

*From Wu J. Carson NL. Myers S. et al. Thc genetic defect in multiple endocrine neoplasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet {in press)
(44).
tMaximum lod score.
tSex difference significant at P < 0.01.

0.35

^Trom Wu J. Carson NL, Myers S, et al. The genetic defect in multiple endocrine neoplasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet (in press)
(44).
PIC = polymorphic information content.

MEN 2A versus

Table 3
Recombination Frequences (6) Between Pairs of Six
Pericentric DNA Markers on Chromosome 10*

Closing in on the Disease Locus with
Flanking Markers
The first flanking marker that we found is at D10S24 (43) but
was rather far from the disease locus (15% recombination) (44).
Twoflankingmarkers, the gene for the beta subunit of the fibronectin receptor (FNRB) (45) and an anonymous sequence at
D10S34 (46), were soon found to be on the short arm and to be
approximately the same distance from the disease locus (about
6% recombination) (44,47), but their order has not yet been established because both of the markers have not been studied in
the same data set. FNRB was physically localized to qll.2 by
Goodfellow et al (45) and shown to be linked to the MEN2A
locus with a lod score of 13.16 at theta = 0.06(44). Nakamura et
al (47) have shown from linkage studies that the anonymous sequence cTBQ14.34 at DI0S34 alsoflanksthe disease locus with
a lod score of 3.61 at theta = 0.07, although they have physically localized the sequence only to lOp in somatic cell hybrid
and monosomic cell lines. Linkage studies between D10S34 and
MEN2A and the relevant markers are currently under way in our
families. As well as the first two markers RBP3 and DI0S5 on
the q arm, Lathrop et al (40) and Nakamura et al (46,47) have
reported an anonymous sequence pMCK2 at DIOS 15 which
physically maps to qll.2 (42). The DIOS 15 marker is linked to
MEN2A with a Iod score of 19.48 at theta = 0.01 (47) and in our
families with a Iod of 17.29 at theta = 0.05 (44). Our multipoint
analysis maps D IOS 15 distally to RBP3 (44). All of the flanking
markers are reasonably informative, and at least some of the
markers wilt be useful in most ofthe families, as indicated by
their polymorphic infonnafion content vatue (13) in Table 1.

The Centromeric Marker
More recently and more importantly, no recombinants have
been found between the centromeric alphoid sequence (DIOZl)
on chromosome 10 isolated by Devilee et al (48) and the
MEN2A locus in two studies (44; C.G. Mathew and B.A.
Ponder, personal communication, 1989). Our data represent
eight male and 18 female informative meioses, of which three
male and eight femate are phase known. This linkage is impor-
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Fig 7—A genetic map offivemarkers flanking the MEN2A locus
showing the shorter male than female map. The distances are
derivedfrom the recombination frequencies in six large families
with MEN 2A (Table 2) and are converted to centimorgans (cM)
using Haldane's function (50). To the left ofthe MEN2A locus is
the p arm and to the right is the q arm of chromosome 10.
tant for identifying those "at risk" members of the MEN 2A
families. The polymorphisms, however, are often noninformative which has led to considerable effort, with some success,
to find more of them (49). The linkage is also important because
it indicates that the MEN2A locus must be very close to the centromere, and possibly the mutation lies in the alphoid sequence,
but we have no evidence of this yet. Moreover, if the disease
locus is not a part of the alphoid DNA (the more likely hypothesis), the finding of a recombinant between it, the disease locus,
and one ofthe close flanking markers will enable us to determine
on which side of the centromere the disease allele lies, which
will make it easier to idenfify the MEN 2A gene.
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I
I

I

ecM I

I

Fig 2—A genetic map of five markers flanking the DIOZl locus
showing the shorter male than female map. The distances are
derived from the recombination frequencies in 15 large families
(Table 3) including the six with MEN 2A in Fig 1 and are converted to centimorgans (cM) using Haldane's function (50). To
the left ofthe DIOZl locus is the p arm and to the right is the q
arm of chromosome 10.
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Sex Difference in Recombination
A remarkable sex difference is seen in the recombination frequencies in the pericentromeric region of chromosome 10 (Tables 2 and 3), resutting in quite different mate and femate maps
(Figs t and 2 [50]). In the six MEN 2A families there were no
obligate male recombinants between the closest flanking markers FNRB and RBP3 and the MEN2A locus (Table 2). The tack
of recombination between RBP3 and MEN2A in mates has atso
been reported by Ponder's group (47) and is evident in the data
from Yamamoto et al (51). It is presumably the case in the data in
which no recombination was reported by Sobol et al (52), but the
data were not separated by sex. The lack of recombination between the markers FNRB, DIOZl, and RBP3 in males but not in
females is significant in our data set with 15 families that includes the MEN 2A families (Table 3) from Wu et al (44).
Lathrop et at (40) and Nakamura et al (46) have also reported sex
differences in the recombination frequencies in this area of the
ctiromosome. These differences have important implications for
genetic counseling for members of the families at risk for having
the MEN 2A gene and mean that the sex of the affected parent
has to be considered. The sex difference in recombination is apparent from DtOS24 on the short arm to RBP3 just below the
centromere on the long arm of the chromosome but interestingly
not immediatety distal on the tong arm (53).
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Fig 3—Pl, P2, P3, andP4 represent loci FNRB, DIOZl, RBP3,
andDlOSlS, respectively. The letters A-F represent haplotypes
derived from several restriction enzyme digests for each locus.
The restriction enzymes are Bqlll, Banll, and Hnfl for FNRB;
Psd and EcoRV for DIOZl; Taql, Bglll, and Mspl for RBP3;
and Rsal for D10S15 (see Table 1). Circled haplotypes are the
most likely ones. See textfor a discussion of the probabilities for
the unaffected members of generations II and III.

Probabilities and Diagnosis

We have reached a stage whereby the RFLPs of closely linked
markers can determine a very high (or low) probability for "at
risk" members of families possessing the allele for this hereditary cancer If the centromeric sequence is informative, probabilities of virtually 0% or 100% can be given and thereby screening could be more selective. For example, in Fig 3 the affected
mother II-2 is informative for the centromeric haplotype A/C.
Since her father had the A/A haplotype and her mother had C/D,
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Fig4—Pl, P2, P3, andP4 represent loci FNRB, DIOZl, RBP3.
and D10S15, respectively. The letters A-F represent haplotypes
derived from several restriction enzyme digests for each locus.
The restriction enzymes are Bglll, Banll, and MsPl for FNRB;
Psd and EcoRV for DIOZl; Taql, BgUl, and Mspl for RBP3;
and Rsal for DIOS 15 (see Table 1). Circled haplotypes are the
most likely ones. See textfor a discussion ofthe probabilities for
the unaffected members of generation II.
the disease allele must be on the chromosome with the A allele at
DIOZl. Both ofher two teenaged sons received her C allele and
are therefore most unlikely to have received the disease allele.
The conclusion is further supported since the mother could only
have received the chromosome with the three loci haplotypes
C C A from her mother and the two sons also received this chromosome, ie, their normal maternal grandmother's chromosome.
In the above case, the flanking markers still gave a very good
probability before we had the centromeric marker infonnation.
Since the haplotypes for FNRB and RBP3 came from the maternal grandmother, the only way that the sons III-l and III-3 could
have received the disease allele is from a double crossover between the two flanking markers. The probability ofthe double
crossover in a female is 0.09 x O.IO = 1% (Table 2).
The probability for the daughter II-5 in Fig 3 as deduced from
the DNA results is not as satisfactory. Her father I-1 is informafive only forthe D IOS 15 locus, and, even for males, the probability of a recombinant child is 5%. However, the daughter is 30
years old and has had negative calcitonin tests. For this reason,
the probability at her age that she has the disease allele is even
less than 5%.
Probabilities of almost certainty can also be deduced when
one or another of the markers FNRB or RBP3 are informative in
an affected father but not when in an affected mother Fig 4 illustrates an example of RBP3 and D IOS 15 being the only informative markers. The affected parent is the fathen and since no
male recombinafion between RBP3 and the MEN2A locus has
been found to date, the probabilities approach 0% or 100% for
the children who still have negafive screening tests. The son II-3
was recently found to have a positive pentagastrin-stimulated
test and had a thyroidectomy with node dissection. He had MTC
with extension to the lymph nodes.
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